Sclerostin Antibody Improves Skeletal Parameters in a Brtl/+ Mouse Model of Osteogenesis Imperfecta

Overview

Journal J Bone Miner Res

Publisher Oxford University Press

Date 2012 Jul 28

PMID 22836659

Citations 73

Authors

Benjamin P Sinder

Mary M Eddy

Michael S Ominsky

Michelle S Caird

Joan C Marini

Kenneth M Kozloff

Affiliations

Soon will be listed here.

Abstract

Osteogenesis imperfecta (OI) is a genetic bone dysplasia characterized by osteopenia and easy susceptibility to fracture. Symptoms are most prominent during childhood. Although antiresorptive bisphosphonates have been widely used to treat pediatric OI, controlled trials show improved vertebral parameters but equivocal effects on long-bone fracture rates. New treatments for OI are needed to increase bone mass throughout the skeleton. Sclerostin antibody (Scl-Ab) therapy is potently anabolic in the skeleton by stimulating osteoblasts via the canonical wnt signaling pathway, and may be beneficial for treating OI. In this study, Scl-Ab therapy was investigated in mice heterozygous for a typical OI-causing Gly→Cys substitution in col1a1. Two weeks of Scl-Ab successfully stimulated osteoblast bone formation in a knock-in model for moderately severe OI (Brtl/+) and in WT mice, leading to improved bone mass and reduced long-bone fragility. Image-guided nanoindentation revealed no alteration in local tissue mineralization dynamics with Scl-Ab. These results contrast with previous findings of antiresorptive efficacy in OI both in mechanism and potency of effects on fragility. In conclusion, short-term Scl-Ab was successfully anabolic in osteoblasts harboring a typical OI-causing collagen mutation and represents a potential new therapy to improve bone mass and reduce fractures in pediatric OI.

Citing Articles

Alendronate partially rescues the periodontal defects in OIM mouse model of osteogenesis imperfecta.

Chen P, Wang K, Lin M, Sharma R, Kalajzic Z, OBrien M Sci Rep. 2025; 15(1):88.

PMID: 39747677 PMC: 11695738. DOI: 10.1038/s41598-024-84756-8.

Beyond bone volume: Understanding tissue-level quality in healing of maxillary vs. femoral defects.

Romanowicz G, Zhang L, Bolger M, Lynch M, Kohn D Acta Biomater. 2024; 187:409-421.

PMID: 39214162 PMC: 11890190. DOI: 10.1016/j.actbio.2024.08.042.

Schnurri-3 inhibition rescues skeletal fragility and vascular skeletal stem cell niche pathology in the OIM model of osteogenesis imperfecta.

Li N, Shi B, Li Z, Han J, Sun J, Huang H Bone Res. 2024; 12(1):46.

PMID: 39183236 PMC: 11345453. DOI: 10.1038/s41413-024-00349-1.

Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

Glorieux F, Langdahl B, Chapurlat R, De Beur S, Sutton V, Poole K J Bone Miner Res. 2024; 39(9):1215-1228.

PMID: 39012717 PMC: 11371902. DOI: 10.1093/jbmr/zjae112.

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives.

Xiaohui T, Wang L, Yang X, Jiang H, Zhang N, Zhang H J Orthop Translat. 2024; 47:39-49.

PMID: 39007037 PMC: 11245887. DOI: 10.1016/j.jot.2024.05.004.

References

Forlino A, Cabral W, Barnes A, Marini J . New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7(9):540-57. PMC: 3443407. DOI: 10.1038/nrendo.2011.81. View

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F . Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286(22):19489-500. PMC: 3103328. DOI: 10.1074/jbc.M110.190330. View

Marini J, Hopkins E, Glorieux F, Chrousos G, Reynolds J, Gundberg C . Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003; 18(2):237-43. DOI: 10.1359/jbmr.2003.18.2.237. View

Davis M, Kovacic B, Marini J, Shih A, Kozloff K . Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta. Bone. 2011; 50(3):784-91. PMC: 3443405. DOI: 10.1016/j.bone.2011.12.007. View

Li J, Mashiba T, Burr D . Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2002; 69(5):281-6. DOI: 10.1007/s002230010036. View

Vahle J, Sato M, Long G, Young J, Francis P, Engelhardt J . Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30(3):312-21. DOI: 10.1080/01926230252929882. View

Poole K, van Bezooijen R, Loveridge N, Hamersma H, Papapoulos S, Lowik C . Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19(13):1842-4. DOI: 10.1096/fj.05-4221fje. View

Letocha A, Cintas H, Troendle J, Reynolds J, Cann C, Chernoff E . Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005; 20(6):977-86. DOI: 10.1359/JBMR.050109. View

Allen M, Reinwald S, Burr D . Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. 2008; 82(5):354-60. PMC: 2698704. DOI: 10.1007/s00223-008-9131-8. View

10.

Busa B, Miller L, Rubin C, Qin Y, Judex S . Rapid establishment of chemical and mechanical properties during lamellar bone formation. Calcif Tissue Int. 2005; 77(6):386-94. DOI: 10.1007/s00223-005-0148-y. View

11.

Uveges T, Kozloff K, Ty J, Ledgard F, Raggio C, Gronowicz G . Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res. 2008; 24(5):849-59. PMC: 2672204. DOI: 10.1359/jbmr.081238. View

12.

Kozloff K, Carden A, Bergwitz C, Forlino A, Uveges T, Morris M . Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res. 2004; 19(4):614-22. DOI: 10.1359/JBMR.040111. View

13.

Donnelly E, Boskey A, Baker S, van der Meulen M . Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. J Biomed Mater Res A. 2009; 92(3):1048-56. PMC: 4160143. DOI: 10.1002/jbm.a.32442. View

14.

Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860-9. DOI: 10.1359/jbmr.080216. View

15.

Mashiba T, Turner C, Hirano T, Forwood M, JOHNSTON C, Burr D . Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001; 28(5):524-31. DOI: 10.1016/s8756-3282(01)00414-8. View

16.

Papapoulos S, Cremers S . Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007; 356(10):1075-6. DOI: 10.1056/NEJMc062792. View

17.

Whyte M, McAlister W, Novack D, Clements K, Schoenecker P, Wenkert D . Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008; 23(10):1698-707. DOI: 10.1359/jbmr.080511. View

18.

Mashiba T, Hirano T, Turner C, Forwood M, JOHNSTON C, Burr D . Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15(4):613-20. DOI: 10.1359/jbmr.2000.15.4.613. View

19.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

20.

Forlino A, Kuznetsova N, Marini J, Leikin S . Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol. 2007; 26(8):604-14. DOI: 10.1016/j.matbio.2007.06.005. View